Then, activation of various inflammatory cells such as macrophages and hepatic stellate cells augments the synthesis of intracellular matrix and subsequent hepatic fibrosis known as metabolic associated steatotic hepatitis (MASH) (Grgurevic et al
Catalase activation decreases H 2 O 2 levels in neuronal cultures and reverses amyloid-induced damage
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics
Antibodies: 3F8, Abagovomab, Abatacept (Orencia), Abciximab (ReoPro), ACZ885 (canakinumab), Adalimumab (Humira), Adecatumumab, Aflibercept, Afutuzumab, Alacizumab pegol, Alemtuzumab (Campath), Altumomab, Afelimomab, Anatumomab mafenatox, Anrukinzumab (IMA-638), Apolizumab, Arcitumomab, Aselizumab, Atlizumab, Atorolimumab, Bapineuzumab, Basiliximab (Simulect), Bavituximab, Bectumomab (LymphoScan), Belatacept, Belimumab (LymphoStat-B), Bertilimumab, Besilesomab, Bevacizumab (Avastin), Biciromab brallobarbital, Bivatuzumab mertansine, Blinatumomab, Canakinumab, Cantuzumab mertansine, Capromab pendetide (Prostascint), Catumaxomab (Removab), Cedelizumab, Certolizumab pegol (Cimzia), Cetuximab (Erbitux), Citatuzumab bogatox, Cixutumumab, Claretuzumab tetraxetan, Clenoliximab, Clivatuzumab tetraxetan, CNTO 148 (golimumab), CNTO 1275 (ustekinumab), Conatumumab, Dacetuzumab, Dacliximab or Daclizumab (Zenapax), Denosumab, Detumomab, Dorlimomab aritox, Dorlixizumab, Drimakinzumab, Ecromeximab, Eculizumab (Soliris), Edobacomab, Edrecolomab (Panorex), Efalizumab (Raptiva), Efungumab (Mycograb), Elsilimomab, Enlimomab pegol, Epitumomab cituxetan, Epratuzumab, Erlizumab, Ertumaxomab (Rexomun), Etanercept (Enbrel), Etaracizumab, Exbivirumab, Fanolesomab (NeutroSpec), Faralimomab, Felvizumab, Figitumumab, Fontolizumab (HuZAF), Foravirumab, Galiximab, Gantenerumab, Gavilimomab, Gemtuzumab ozogamicin (Mylotarg), Ginakinzumab, Golimumab, Gomiliximab, Ibalizumab, Ibritumomab tiuxetan (Zevalin), Igovomab, Imciromab, Infliximab (Remicade), Inolimomab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Ixutumumab, Keliximab, Labetuzumab, Lemalesomab, Lebrilizumab, Lerdelimumab, Lexatumumab, Libivirumab, Lintuzumab, Lucatumumab, Lumiliximab, Mapatumumab, Maslimomab, Matuzumab, Mepolizumab (Bosatria), Metelimumab, Milatuzumab, Minretumomab, Mitumomab, Morolimumab, Motavizumab (Numax), Muromonab, MYO-029 (stamulumab), Nacolomab tafenatox, Naptumomab estafenatox, Natalizumab (Tysabri), Nebacumab, Nerelimomab, Nimotuzumab (BIOMAbEGFR), Nofetumomab merpentan (Verluma), Ocrelizumab, Odulimomab, Ofatumumab, Omalizumab (Xolair), Oregovomab (OvaRex), Otelixizumab, Pagibaximab, Palivizumab (Synagis), Pamtuzumab tetraxetan, Panitumumab (Vectibix), Pascolizumab, Pemtumomab (Theragyn), Pertuzumab (Omnitarg), Pexelizumab, Pintumomab, Priliximab, Pritumumab, PRO 140, Rafivirumab, Ramucirumab, Ranibizumab (Lucentis), Raxibacumab, Regavirumab, Reslizumab, Rilonacept (Arcalyst), Rintalizumab, Rituximab (MabThera, Rituxan), Robatumumab, Rovelizumab, Ruplizumab, Satumomab, Sevirumab, Sibrotuzumab, Siplizumab, Sonepcizumab, Sontuzumab, Stamulumab, Stolanezumab, Sulesomab (LeukoScan), Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tanezumab, Taplitumomab paptox, Tefibazumab (Aurexis), Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, TGN1412, Ticilimumab (tremelimumab), Tigatuzumab, TNX-355 (ibalizumab), TNX-650, TNX-901 (talizumab), Tocilizumab (Actemra), Toralizumab, Tositumomab (Bexxar), Trastuzumab (Herceptin), Tremelimumab, Tucotuzumab celmoleukin, Tuvirumab, Urtoxazumab, Ustekinumab, Vapaliximab, Vedolizumab, Veltuzumab, Vepalimomab, Vimakinzumab, Visilizumab (Nuvion), Volociximab, Vontakinzumab, Votumumab (HumaSPECT), Zalutumumab, Zanolimumab (HuMax-CD4), Ziralimumab, Zolimomab aritox, or the functional (epitope-binding) fragments thereof
Eshelman Innovation helped bring expertise from business, marketing, manufacturing, government regulation and law
Borisovs, V., Bodrenko, J., Kalnina, J
